INX-189: Preliminary Phase Ia data

In a double-blind, placebo-controlled Phase Ia trial in 42 healthy volunteers, single-ascending doses of 3-100 mg oral INX-189 were well tolerated with no drug-related serious adverse events. Inhibite...